• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Brain tumor pathology >Glioblastomas harboring gene fusions detected by next-generation sequencing
【24h】

Glioblastomas harboring gene fusions detected by next-generation sequencing

机译：Glioblastomas harboring gene fusions detected by next-generation sequencing

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Abstract Oncogenic gene fusions have been reported in diffuse gliomas and may serve as potential therapeutic targets. Here, using next-generation sequencing analysis (Illumina TruSight Tumor 170 panel), we analyzed a total of 356 diffuse gliomas collected from 2017 to 2019 to evaluate clinical, pathological, and genetic features of gene fusion. We found 53 cases of glioblastomas harboring the following oncogenic gene fusions: MET (n?=?18), EGFR (n?=?14), FGFR (n?=?12), NTRK (n?=?5), RET (n?=?2), AKT3 (n?=?1), and PDGFRA fusions (n?=?1). Gene fusions were consistently observed in both IDH-wildtype and IDH-mutant glioblastomas (8.8 and 9.4, p?=?1.000). PTPRZ1–MET fusion was the only fusion that genetically resembled secondary glioblastomas (i.e., high frequency of IDH mutation, ATRX loss, TP53 mutation, and absence of EGFR amplification), whereas other gene fusion types were similar to primary glioblastomas (i.e., high frequency of IDH-wildtype, TERT mutation, EGFR amplification, and PTEN mutation). In IDH-wildtype glioblastoma patients, multivariable analysis revealed that the PTPRZ1–MET fusion was associated with poor progression-free survival (HR 95 CI: 5.42 (1.72–17.05), p?=?0.004). Additionally, we described two novel cases of CCDC6–RET fusion in glioma. Collectively, our findings indicate that targetable gene fusions are associated with aggressive biological behavior and can aid the clinical treatment strategy for glioma patients.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号